TJPC announced that its subsidiary Tianyao Heping Pharmaceutical Co., Ltd. has received the "Drug Registration Certificate" for Difluprednate Eye Drops issued by the National Medical Products Administration. This drug is mainly used to treat inflammation and pain related to eye surgery. Tianyao Heping has invested approximately 53.2734 million yuan in research and development for this project. Currently, Difluprednate Eye Drops is the first generic drug in the country. The global sales are projected to be USD 33 million and USD 24 million for 2023 and 2024, respectively